Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $61,874 | 10 | 76.8% |
| Unspecified | $18,525 | 3 | 23.0% |
| Food and Beverage | $212.46 | 3 | 0.3% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Shire North American Group Inc | $76,439 | 12 | $0 (2019) |
| Alexion Pharmaceuticals, Inc. | $4,109 | 3 | $0 (2019) |
| AstraZeneca Pharmaceuticals LP | $63.60 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2019 | $46,275 | 9 | Shire North American Group Inc ($46,094) |
| 2018 | $22,325 | 4 | Shire North American Group Inc ($22,325) |
| 2017 | $12,011 | 3 | Shire North American Group Inc ($8,020) |
All Payment Transactions
16 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 06/25/2019 | Shire North American Group Inc | — | Consulting Fee | Cash or cash equivalent | $2,185.00 | General |
| 05/21/2019 | Shire North American Group Inc | — | Consulting Fee | Cash or cash equivalent | $5,890.00 | General |
| 03/19/2019 | Shire North American Group Inc | — | Consulting Fee | Cash or cash equivalent | $4,180.00 | General |
| 03/18/2019 | AstraZeneca Pharmaceuticals LP | IMFINZI (Drug) | Food and Beverage | In-kind items and services | $63.60 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 03/05/2019 | Alexion Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $117.49 | General |
| 02/12/2019 | Shire North American Group Inc | — | Consulting Fee | Cash or cash equivalent | $9,975.00 | General |
| 02/12/2019 | Shire North American Group Inc | — | Consulting Fee | Cash or cash equivalent | $8,569.00 | General |
| 01/08/2019 | Shire North American Group Inc | — | Consulting Fee | Cash or cash equivalent | $8,170.00 | General |
| 01/08/2019 | Shire North American Group Inc | — | Consulting Fee | Cash or cash equivalent | $7,125.00 | General |
| 10/09/2018 | Shire North American Group Inc | CINRYZE (Drug) | — | Cash or cash equivalent | $7,915.00 | Research |
| Study: A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CINRYZE C1 ESTERASE INHIBITOR HUMAN FOR THE TREATMENT OF ACUTE ANTIBODY-MEDIATED REJECTION IN KIDNEY TRANSPLANT PATIENTS • Category: IMMUNOLOGY | ||||||
| 10/09/2018 | Shire North American Group Inc | CINRYZE (Drug) | — | Cash or cash equivalent | $1,110.00 | Research |
| Study: A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CINRYZE C1 ESTERASE INHIBITOR HUMAN FOR THE TREATMENT OF ACUTE ANTIBODY-MEDIATED REJECTION IN KIDNEY TRANSPLANT PATIENTS • Category: IMMUNOLOGY | ||||||
| 09/25/2018 | Shire North American Group Inc | CINRYZE (Drug) | — | Cash or cash equivalent | $9,500.00 | Research |
| Study: A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CINRYZE C1 ESTERASE INHIBITOR HUMAN FOR THE TREATMENT OF ACUTE ANTIBODY-MEDIATED REJECTION IN KIDNEY TRANSPLANT PATIENTS • Category: IMMUNOLOGY | ||||||
| 08/28/2018 | Shire North American Group Inc | — | Consulting Fee | Cash or cash equivalent | $3,800.00 | General |
| 04/19/2017 | Shire North American Group Inc | — | Consulting Fee | Cash or cash equivalent | $8,020.00 | General |
| 03/05/2017 | Alexion Pharmaceuticals, Inc. | SOLIRIS (Drug) | Food and Beverage | In-kind items and services | $31.37 | General |
| Category: Immunology | ||||||
| 02/08/2017 | Alexion Pharmaceuticals, Inc. | SOLIRIS (Drug) | Consulting Fee | Cash or cash equivalent | $3,960.00 | General |
| Category: Immunology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CINRYZE C1 ESTERASE INHIBITOR HUMAN FOR THE TREATMENT OF ACUTE ANTIBODY-MEDIATED REJECTION IN KIDNEY TRANSPLANT PATIENTS | Shire North American Group Inc | $18,525 | 3 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2020 | 6 | 151 | 337 | $42,845 | $9,146 |
All Medicare Procedures & Services
6 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 88350 | Antibody evaluation | Facility | 2020 | 19 | 179 | $21,350 | $4,664 | 21.8% |
| 88346 | Antibody evaluation | Facility | 2020 | 45 | 49 | $8,036 | $1,559 | 19.4% |
| 88348 | Electron microscopy for diagnosis | Facility | 2020 | 20 | 20 | $6,336 | $1,376 | 21.7% |
| 88305 | Pathology examination of tissue using a microscope, intermediate complexity | Facility | 2020 | 18 | 18 | $2,826 | $610.12 | 21.6% |
| 84181 | Protein measurement | Facility | 2020 | 30 | 30 | $2,232 | $491.07 | 22.0% |
| 88313 | Special stained specimen slides to examine tissue including interpretation and report | Facility | 2020 | 19 | 41 | $2,065 | $444.59 | 21.5% |
About Dr. Robert Colvin, MD
Dr. Robert Colvin, MD is a Immunopathology healthcare provider based in Boston, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/26/2005. The National Provider Identifier (NPI) number assigned to this provider is 1922098458.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Robert Colvin, MD has received a total of $80,611 in payments from pharmaceutical and medical device companies, with $46,275 received in 2019. These payments were reported across 16 transactions from 3 companies. The most common payment nature is "Consulting Fee" ($61,874).
As a Medicare-enrolled provider, Colvin has provided services to 151 Medicare beneficiaries, totaling 337 services with total Medicare billing of $9,146. Data is available for 1 year (2020–2020), covering 6 distinct procedure/service records.
Practice Information
- Specialty Immunopathology
- Other Specialties Anatomic Pathology
- Location Boston, MA
- Active Since 10/26/2005
- Last Updated 09/11/2025
- Taxonomy Code 207ZI0100X
- Entity Type Individual
- NPI Number 1922098458
Products in Payments
- CINRYZE (Drug) $18,525
- SOLIRIS (Drug) $3,991
- IMFINZI (Drug) $63.60
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.